Protocol of discovery and validation of the breast cancer survival predictor
algorithm. We hypothesized that clinically relevant genetic signatures could be found by searching for clusters of co-regulated genes that display highly concordant transcript abundance behavior across multiple experimental models and clinical settings which are modeling or representing malignant phenotypes of interest (1) (2) (3) (4) . Thus, according to this model the primary criterion in transcript selection process should be the concordance of changes in expression rather than a magnitude of changes (e.g., fold change). One of the predictions of this model is that transcripts of interest would be expected to have a tightly controlled "rank order" of expression within a cluster of co-regulated genes reflecting a balance of up-and down-regulated mRNAs as a desired regulatory end-point in a cell. A degree of resemblance of the transcript abundance rank order within a gene cluster between a test sample and reference standard is measured by a Pearson correlation coefficient and designated as a phenotype association index (PAI). To identify genes with consistently concordant expression patterns across multiple data sets and various experimental conditions, we compared the expression profile of 70 genes in clinical samples (test samples) to the expression profiles of transcripts differentially regulated in multiple established human breast cancer cell lines (reference standard).
The transcripts comprising each breast cancer survival predictor signature were selected based on Pearson correlation coefficients (r > 0.95) reflecting a degree of similarity of expression profiles in clinical tumor samples (metastatic versus nonmetastatic tumors) and experimental samples using the following protocol.
Step 1. Expression profiles of transcripts comprising 70-gene signature were independently quantified for each experimental conditions (see below) and clinical samples (training set of 78 breast cancer samples) using the quantitative RT-PCR protocol and Affymetrix microarray processing and statistical analysis software package (for U95Av2 microarray data sets) as described in Materials and Methods.
Step (Figure 1 ; Tables 1 and S1).
Step 5. We used the Kaplan-Meier survival analysis to assess the prognostic power of each best performing cluster in predicting the probability that patients would remain disease-free after therapy (Figures 1-7; Tables 1, 2, and S1). We selected the prognosis discrimination cut-off value for each signature based on highest level of statistical significance in patient's stratification into poor and good prognosis groups as determined by the log-rank test (lowest P value and highest hazard ratio; Table S1 &   Figures 1, 2 , & S1). Clinical samples having the Pearson correlation coefficient at or higher the cut-off value were identified as having the poor prognosis signature. Clinical samples with the Pearson correlation coefficient lower the cut-off value were identified as having the good prognosis signature.
Step 6. We developed a breast cancer survival predictor algorithm taking into account calls from all four individual signatures. We accepted the prognosis discrimination cut-off value for all four signatures based on highest level of statistical significance in patient's stratification into poor and good prognosis groups as determined by the Kaplan-Meier survival analysis (lowest P value and highest hazard ratio defined by the log-rank test; Table S1 & Figures 2 and S1). Clinical samples having at least two poor survival signatures were stratified into the poor prognosis sub-group. Clinical samples exhibiting at least three good survival signatures were stratified into the good prognosis sub-groups (Table S1 ).
Step 7. We validated the prognostic power of breast cancer survival predictor signatures alone and in combination with the established markers of outcome using an independent set of clinical samples obtained from 295 breast cancer patients (Figures 2-7; Table S1 ).
Quantitative reverse-transcription polymerase chain reaction (Q-RT-PCR)
analysis protocol. Quantitative RT-PCR analysis of transcripts abundance levels for genes of the breast cancer survival predictor cluster was performed using an ABI7900 instrument (Applied Biosystems, Foster City, CA). Primer design, assay validation, and Q-PCR analysis were performed as previously described (27-29) and according to the vendor's recommended protocols (http://appliedbiosystems.com/support/tutorials/). For quantification, a reference curve was generated for each gene by amplifying serial dilution of cDNA and expression values were normalized using GAPDH and mRNA from normal human breast epithelial cell line (Clonetics/BioWhittaker, San Diego, CA) as controls. Each 15 µl reaction contained 5 µl primers (0.3 µM); 2.5 µl cDNA; 7.5 µl CyBr Green Myx (Apllied Biosystems, Foster City, CA) and was started at 95 0 C for 10 min and carried out for 45 cycles (94 0 C, 10 sec; 60 0 C, 20 sec; 72 0 C, 30 sec). Primer sequences are shown in the Supplementary Table S3 . Legend: 295 breast cancer patients were classified according to whether they had a good-prognosis signature or poor-prognosis signature defined by individual therapy outcome predictor signatures. Kaplan-Meier analysis was performed to evaluate the probability that patients would survive according to whether they had a poor-prognosis or a good-prognosis signature and determine the proportion of patients who would survive at least 5 or 10 years after therapy in poor-prognosis and good-prognosis sub-groups. Hazard ratios, 95% confidence intervals, and P values were calculated with use of the log-rank test. The number of correct predictions in poor-prognosis and good-prognosis groups is shown as a fraction of patients with the observed clinical outcome after therapy (79 patients died and 216 patients remained alive). The classification performance of different signatures were evaluated using one common threshold level (0.00) and optimized threshold levels adjusted for each gene cluster to achieve the most statistically significant (highest hazard ratio and lowest P value) discrimination in survival probability between patients assigned to poor and good prognosis groups. Legend: The estimate of potential therapeutic benefits is made in the cohort of 295 breast cancer patients (21) and based on the assumption that the use of additional cycle(s) of adjuvant systemic therapy would be prescribed to patients classified into poor prognosis sub-groups. In the cohort of 295 breast cancer patients, ten of 151 (6.6%) patients who had lymph node-negative disease and 120 of the 144 (83.3%) patients who had lymph node-positive disease had received adjuvant systemic therapy (21). We accepted the actual 5-and 10-year survival in the corresponding classification categories as the expected therapy outcome for a given subgroup. We assumed that each additional cycle of adjuvant systemic therapy would result in the same therapy outcome as was actually documented in the most relevant sub-groups of the 295 patients. Therapy outcome for patients classified into poor prognosis subgroups and treated with additional cycle(s) of adjuvant systemic therapy is expected to be in 37% of patients in good therapy outcome category for ER+LN+ and ER+LN-poor signature sub-groups and in 41% of patients in good therapy outcome category for ER-LN+ and ER-LN-poor signature sub-groups. Figure S1 . Kaplan-Meier analysis of the survival probability among 295 breast cancer patients comprising a signature validation group according to whether they had a good-prognosis or poor-prognosis defined by the 14-gene survival predictor signature. 295 patients were stratified into sub-groups using the values of the 14-gene expression profile at the different cut-off levels (panels A-E) or into sub-groups using a 10% increment from bottom to top values of the 14-gene expression profile (panel F). Statistical significance of the differences in the survival probability between sub-groups was assessed using Chi square and log rank tests. In the panel F, differences in the survival probability between sub-groups was at the p <0.0001 levels. 
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